UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 11.505

Sortiert nach

Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey

Journal of antimicrobial chemotherapy, 2020-11, Vol.75 (11), p.3386-3390

2020

Link zum Volltext

Verfügbarkeit prüfen

Recent Approaches to Targeting Canonical NF κ B Signaling in the Early Inflammatory Response to Renal IRI

Journal of the American Society of Nephrology, 2021-09, Vol.32 (9), p.2117-2124

2021

Link zum Volltext

Verfügbarkeit prüfen

Comparison of GPS TEC with modelled values from IRI 2016 and IRI-PLAS over Istanbul, Turkey

Astrophysics and space science, 2018-11, Vol.363 (11), p.1-9, Article 231

Atıcı, Ramazan

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS621-TPS621

2022

Link zum Volltext

Verfügbarkeit prüfen

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16116-e16116

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4190-TPS4190

2023

Link zum Volltext

Verfügbarkeit prüfen

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Annals of oncology, 2020-09, Vol.31, p.S1056-S1056

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.TPS778-TPS778

2023

Link zum Volltext

Verfügbarkeit prüfen

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

Annals of oncology, 2017-10, Vol.28 Suppl 9, p.ix74

2017

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4196-TPS4196

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.TPS619-TPS619

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4170-TPS4170

2021

Link zum Volltext

Verfügbarkeit prüfen

P31-3 Real-world treatment outcomes of nal-IRI+5FU/LV in unresectable pancreatic cancer

Annals of oncology, 2023-11, Vol.34, p.S1453-S1453

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS446-TPS446

2021

Link zum Volltext

Verfügbarkeit prüfen

P-26 Is there room for nal-IRI in biliary tract cancer?

Annals of oncology, 2023-06, Vol.34, p.S22-S22

2023

Link zum Volltext

Verfügbarkeit prüfen

MSC-Derived Small Extracellular Vesicles Exert Cardioprotective Effect Through Reducing VLCFAs and Apoptosis in Human Cardiac Organoid IRI Model

Stem cells (Dayton, Ohio), 2024-05, Vol.42 (5), p.416

2024

Link zum Volltext

Verfügbarkeit prüfen

Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation

International journal of pharmaceutics, 2020-08, Vol.586, p.119522, Article 119522

2020

Link zum Volltext

Verfügbarkeit prüfen

Assessing dispositional empathy in adults: A French validation of the Interpersonal Reactivity Index (IRI)

Canadian journal of behavioural science, 2013-01, Vol.45 (1), p.42-48

2013

Link zum Volltext

Verfügbarkeit prüfen

Testing the Psychometric Properties of the Interpersonal Reactivity Index (IRI) in Chile: Empathy in a Different Cultural Context

European journal of psychological assessment : official organ of the European Association of Psychological Assessment, 2011, Vol.27 (3), p.179-185

2011

Link zum Volltext

Verfügbarkeit prüfen

OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3580-3580

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open-label pilot study evaluating the safety and activity of Nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study) (NCT03483038)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.TPS790-TPS790

2020

Link zum Volltext

Verfügbarkeit prüfen

The protective effect of isoflurane pretreatment on liver IRI by suppressing noncanonical pyroptosis of liver macrophages

International immunopharmacology, 2021-10, Vol.99, p.107977-107977, Article 107977

2021

Link zum Volltext

Verfügbarkeit prüfen

Prediction of early treatment failure of second-line nal-iri/5-FU/FA in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.721-721

2023

Link zum Volltext

Verfügbarkeit prüfen

Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5586-5586

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 11.505

Suche als RSS-Feed

Aktive Filter

ThemaInternal Medicine

ThemaMarketing

ThemaMiddle Aged

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(11.199)
Mit Volltextzugriff
(10.279)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(11.477)
Japanisch
(1.254)
Französisch
(25)
Spanisch
(19)
Deutsch
(18)
Norwegisch
(6)
Portugiesisch
(6)
Russisch
(1)

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(258)
Canadian Journal Of Physiology And Pharmacology
(252)
American Journal Of Transplantation
(246)
Nature
(216)
Diabetes
(205)
The Faseb Journal
(136)
亚太热带医药杂志:英文版
(130)
Annals Of Oncology
(110)
Asian Pacific Journal Of Tropical Medicine
(109)
The Journal Of Clinical Investigation
(108)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(66)
... seit 30 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey

Recent Approaches to Targeting Canonical NF κ B Signaling in the Early Inflammatory Response to Renal IRI

Comparison of GPS TEC with modelled values from IRI 2016 and IRI-PLAS over Istanbul, Turkey

Randomized phase II study of nalicap (nal-IRI/capecitabine) compared to NAPOLI (nal-IRI/5-FU/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress

Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

1838P Do irinotecan (IRI) dose reductions driven by UGT1A128 genotyping prevent IRI-related severe neutropenia? A real-world study

Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI)

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

WJOG6510G: Randomized phase II of Pmab + IRI vs Cmab + IRI for KRAS WT mCRC previously treated after FU, IRI, and L-OHP

A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038)

P31-3 Real-world treatment outcomes of nal-IRI+5FU/LV in unresectable pancreatic cancer

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study)

P-26 Is there room for nal-IRI in biliary tract cancer?

MSC-Derived Small Extracellular Vesicles Exert Cardioprotective Effect Through Reducing VLCFAs and Apoptosis in Human Cardiac Organoid IRI Model

Tuning the pharmacokinetics and efficacy of irinotecan (IRI) loaded gelatin nanoparticles through folate conjugation

Assessing dispositional empathy in adults: A French validation of the Interpersonal Reactivity Index (IRI)

Testing the Psychometric Properties of the Interpersonal Reactivity Index (IRI) in Chile: Empathy in a Different Cultural Context

OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer

A phase II, open-label pilot study evaluating the safety and activity of Nal-IRI in combination with 5-FU and oxaliplatin in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study) (NCT03483038)

The protective effect of isoflurane pretreatment on liver IRI by suppressing noncanonical pyroptosis of liver macrophages

Prediction of early treatment failure of second-line nal-iri/5-FU/FA in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)

Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma

Aktive Filter

Suchergebnisse filtern